Background/Aims: NSAID-induced enteropathy has been the focus of recent basic and clinical research subsequent to the development of the capsule endoscope and double-balloon endoscope. We review the possible pathogenic mechanisms underlying NSAID-induced enteropathy and discuss the role of the inhibition of COX-1/COX-2 and the influences of food as well as various prophylactic treatments on these lesions. Methods: Studies were performed in experimental animals. Results: Multiple factors, such as intestinal hypermotility, decreased mucus secretion, enterobacteria, and upregulation of iNOS/NO expression, are involved in the pathogenesis of NSAID-induced enteropathy, in addition to the decreased production of PGs due to the inhibition of COX. Enterobacterial invasion is the most important pathogenic event, and intestinal hypermotility, which was associated with this event, is essential for the development of these lesions. NSAIDs also upregulate the expression of COX-2, and the inhibition of both COX-1 and COX-2 is required for the intestinal ulcerogenic properties of NSAIDs to manifest. NSAID-induced enteropathy is prevented by PGE2, atropine, ampicillin, and aminoguanidine as well as soluble dietary fiber, and exacerbated by antisecretory drugs such as proton pump inhibitors. Conclusion: These findings on the pathogenesis of NSAID-induced enteropathy will be useful for the future development of intestinal-sparing alternatives to standard NSAIDs.

Journal Section:
Invited Review
Keywords:
NSAID-induced enteropathy, Pathogenic mechanism, Prophylactic drugs, Dietary components, COX-1/COX-2 inhibition
1.
Robert A, Asano T: Resistance of germfree rats to indomethacin-induced intestinal lesions. Prostaglandins 1977;14:333-341.
[PubMed]
https://doi.org/10.1016/0090-6980(77)90178-2
2.
Graham DY, Opekun AR, Willingham FF, Qureshi WA: Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol 2005;3:55-59.
[PubMed]
https://doi.org/10.1016/S1542-3565(04)00603-2
3.
Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I: A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005;128:1172-1178.
[PubMed]
https://doi.org/10.1053/j.gastro.2005.03.020
4.
Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Aisenberg J, Bhadra P, Berger MF: Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol Ther 2007;25:1211-1222.
[PubMed]
https://doi.org/10.1111/j.1365-2036.2007.03312.x
5.
Matsumoto T, Kudo T, Esaki M, Yano T, Yamamoto H, Sakamoto C, Goto H, Nakase H, Tanaka S, Matsui T, Sugano K, Iida M: Prevalence of non-steroidal anti-inflammatory drug-induced enteropathy determined by double-balloon endoscopy: a Japanese multicenter study. Scand J Gastroenterol 2008;43:490-496.
[PubMed]
https://doi.org/10.1080/00365520701794121
6.
Fujimori S, Takahashi Y, Seo T, Gudis K, Ehara A, Kobayashi T, Mitsui K, Yonezawa M, Tanaka S, Tatsuguchi A, Sakamoto C: Prevention of traditional NSAID-induced small intestinal injury: recent preliminary studies using capsule endoscopy. Digestion 2010;82:167-172.
[PubMed]
https://doi.org/10.1159/000308361
7.
Whittle BJ: Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat. Gastroenterology 1981;80:94-98.
[PubMed]
8.
Tanaka A, Kunikata T, Mizoguchi H, Kato S, Takeuchi K: Dual action of nitric oxide in pathogenesis of indomethacin-induced small intestinal ulceration in rats. J Physiol Pharmacol 1999;50:405-417.
[PubMed]
9.
Konaka A, Kato S, Tanaka A, Kunikata T, Korolkiewicz R, Takeuchi K: Roles of enterobacteria, nitric oxide and neutrophil in pathogenesis of indomethacin-induced small intestinal lesions in rats. Pharmacol Res 1999;40:517-524.
[PubMed]
https://doi.org/10.1006/phrs.1999.0550
10.
Kunikata T, Tanaka A, Miyazawa T, Kato S, Takeuchi K: 16,16-Dimethyl prostaglandin E2 inhibits indomethacin-induced small intestinal lesions through EP3 and EP4 receptors. Dig Dis Sci 2002;47:894-904.
[PubMed]
https://doi.org/10.1023/A:1014725024519
11.
Blackler RW, Gemici B, Manko A, Wallace JL: NSAID-gastroenteropathy: new aspects of pathogenesis and prevention. Curr Opin Pharmacol 2014;19:11-16.
[PubMed]
https://doi.org/10.1016/j.coph.2014.05.008
12.
Kargman S, Charleson S, Cartwright M, Frank J, Riendeau D, Mancini J, Evans J, O'Neill G: Characterization of Prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 1996;111:445-454.
[PubMed]
https://doi.org/10.1053/gast.1996.v111.pm8690211
13.
Chan CC, Boyce S, Brideau C, Ford-Hutchinson AW, Gordon R, Guay D, Hill RG, Li CS, Mancini J, Panneton M, et al: Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther 1995;274:1531-1537.
[PubMed]
14.
Wallace JL, McKnight W, Reuter BK, Vergnolle N: NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000;119:706-714.
[PubMed]
https://doi.org/10.1053/gast.2000.16510
15.
Tanaka A, Araki H, Komoike Y, Hase S, Takeuchi K: Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal antiinflammatory drugs. J Physiol Paris 2001;95:21-27.
[PubMed]
https://doi.org/10.1016/S0928-4257(01)00005-5
16.
Tanaka A, Hase S, Miyazawa T, Takeuchi K: Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage. J Pharmacol Exp Ther 2002;300:754-761.
[PubMed]
https://doi.org/10.1124/jpet.300.3.754
17.
Laine L, Takeuchi K, Tarnawski A: Gastric mucosal defense and cytoprotection: bench to bedside. Gastroenterology 2008;135:41-60.
[PubMed]
https://doi.org/10.1053/j.gastro.2008.05.030
18.
Tanaka A, Hase S, Miyazawa T, Ohno R, Takeuchi K: Role of cyclooxygenase (COX)-1 and COX-2 inhibition in nonsteroidal anti-inflammatory drug-induced intestinal damage in rats: relation to various pathogenic events. J Pharmacol Exp Ther 2002;303:1248-1254.
[PubMed]
https://doi.org/10.1124/jpet.102.041715
19.
Takeuchi K, Miyazawa T, Tanaka A, Kato S, Kunikata T: Pathogenic importance of intestinal hypermotility in NSAID-induced small intestinal damage in rats. Digestion 2002;66:30-41.
[PubMed]
https://doi.org/10.1159/000064419
20.
Satoh H, Shiotani S, Otsuka N, Hatao K, Nishimura S: Role of dietary fibres, intestinal hypermotility and leukotrienes in the pathogenesis of NSAID-induced small intestinal ulcers in cats. Gut 2009;58:1590-1596.
[PubMed]
https://doi.org/10.1136/gut.2008.156596
21.
Satoh H, Hara T, Murakawa D, Matsuura M, Takata K: Soluble dietary fiber protects against nonsteroidal anti-inflammatory drug-induced damage to the small intestine in cats. Dig Dis Sci 2010;55:1264-1271.
[PubMed]
https://doi.org/10.1007/s10620-009-0893-2
22.
Takeuchi K, Hase S, Mizoguchi H, Komoike Y, Tanaka A: Protection by aspirin of indomethacin-induced small intestinal damage in rats: mediation by salicylic acid. J Physiol Paris 2001;95:51-57.
[PubMed]
https://doi.org/10.1016/S0928-4257(01)00009-2
23.
Komoike Y, Takeeda M, Tanaka A, Kato S, Takeuchi K: Prevention by parenteral aspirin of indomethacin-induced gastric lesions in rats: mediation by salicylic acid. Dig Dis Sci 2002;47:1538-1545.
[PubMed]
https://doi.org/10.1023/A:1015867119014
24.
Maiden L, Thjodleifsson B, Seigal A, Bjarnason II, Scott D, Birgisson S, Bjarnason I: Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol 2007;5:1040-1045.
[PubMed]
https://doi.org/10.1016/j.cgh.2007.04.031
25.
Maehata Y, Esaki M, Morishita T, Kochi S, Endo S, Shikata K, Kobayashi H, Matsumoto T: Small bowel injury induced by selective cyclooxygenase-2 inhibitors: a prospective, double-blind, randomized clinical trial comparing celecoxib and meloxicam. J Gastroenterol 2012;47:387-393.
[PubMed]
https://doi.org/10.1007/s00535-011-0501-z
26.
Inoue T, Iijima H, Arimitsu J, Hagihara K, Kawai S, Shiraishi E, Hiyama S, Mukai A, Shinzaki S, Nishida T, Ogata A, Tsujii M, Takehara T: Amelioration of small bowel injury by switching from nonselective nonsteroidal anti-inflammatory drugs to celecoxib in rheumatoid arthritis patients: a pilot study. Digestion 2014;89:124-132.
[PubMed]
https://doi.org/10.1159/000357229
27.
Filaretova L, Tanaka A, Komoike Y, Takeuchi K: Selective cyclooxygenase-2 inhibitor induces gastric mucosal damage in adrenalectomized rats. Inflammopharmacology 2002;10:413-422.
https://doi.org/10.1163/156856002321544882
28.
Kato S, Ogawa Y, Kanatsu K, Okayama M, Watanabe T, Arakawa T, Takeuchi K: Ulcerogenic influence of selective cyclooxygenase-2 inhibitors in the rat stomach with adjuvant-induced arthritis. J Pharmacol Exp Ther 2002;303:503-509.
[PubMed]
https://doi.org/10.1124/jpet.102.040659
29.
Takeuchi K: Pathogenesis of NSAID-induced gastric damage: importance of cyclooxygenase inhibition and gastric hypermotility. World J Gastroenterol 2012;18:2147-2160.
[PubMed]
https://doi.org/10.3748/wjg.v18.i18.2147
30.
Rachmilewitz D, Stamler JS, Karmeli F, Mullins ME, Singel DJ, Loscalzo J, Xavier RJ, Podolsky DK: Peroxynitrite-induced rat colitis - a new model of colonic inflammation. Gastroenterology 1993;105:1681-1688.
[PubMed]
31.
Mizoguchi H, Ogawa Y, Kanatsu K, Tanaka A, Kato S, Takeuchi K: Protective effect of rebamipide on indomethacin-induced intestinal damage in rats. J Gastroenterol Hepatol 2001;16:1112-1119.
[PubMed]
https://doi.org/10.1046/j.1440-1746.2001.02592.x
32.
Tanaka A, Mizoguchi H, Kunikata T, Miyazawa T, Takeuchi K: Protection by constitutively formed nitric oxide of intestinal damage induced by indomethacin in rats. J Physiol Paris 2001;95:35-41.
[PubMed]
https://doi.org/10.1016/S0928-4257(01)00007-9
33.
Ohno R, Yokota A, Tanaka A, Takeuchi K: Induction of small intestinal damage in rats following combined treatment with cyclooxygenase-2 and nitric-oxide synthase inhibitors. J Pharmacol Exp Ther 2004;310:821-827.
[PubMed]
https://doi.org/10.1124/jpet.104.065961
34.
Takahira Y, Izumi N, Tanaka A, Takeuchi K: Importance of bile acids in COX-2 and iNOS expressions as well as lesion formation in rat small intestines following administration of indomethacin: relation to farnesoid X receptors. Gastroenterology 2007;132:A-565.
35.
Kamei K, Kubo Y, Kato N, Hatazawa R, Amagase K, Takeuchi K: Prophylactic effect of irsogladine maleate against indomethacin-induced small intestinal lesions in rats. Dig Dis Sci 2008;53:2657-2666.
[PubMed]
https://doi.org/10.1007/s10620-008-0199-9
36.
Kato N, Mashita Y, Kato S, Mitsufuji S, Yoshikawa T, Takeuchi K: Sildenafil, an inhibitor of phosphodiesterase subtype 5, prevents indomethacin-induced small-intestinal ulceration in rats via a NO/cGMP-dependent mechanism. Dig Dis Sci 2009;54:2346-2356.
[PubMed]
https://doi.org/10.1007/s10620-008-0646-7
37.
Kato S, Tanaka A, Kunikata T, Umeda M, Takeuchi K: Protective effect of lafutidine against indomethacin-induced intestinal ulceration in rats: relation to capsaicin-sensitive sensory neurons. Digestion 2000;61:39-46.
[PubMed]
https://doi.org/10.1159/000007734
38.
Satoh H, Takeuchi K: Management of NSAID/aspirin-induced small intestinal damage by GI-sparing NSAIDs, anti-ulcer drugs and food constituents. Curr Med Chem 2012;19:82-89.
[PubMed]
https://doi.org/10.2174/092986712803413980
39.
Amagase K, Ochi A, Sugihara T, Kato S, Takeuchi K: Protective effect of lafutidine, a histamine H2 receptor antagonist, against loxoprofen-induced small intestinal lesions in rats. J Gastroenterol Hepatol 2010;25(suppl 1):S111-S118.
[PubMed]
https://doi.org/10.1111/j.1440-1746.2010.06223.x
40.
Yoda Y, Amagase K, Kato S, Tokioka S, Murano M, Kakimoto K, Nishio H, Umegaki E, Takeuchi K, Higuchi K: Prevention by lansoprazole, a proton pump inhibitor, of indomethacin-induced small intestinal ulceration in rats through induction of heme oxygenase-1. J Physiol Pharmacol 2010;61:287-294.
[PubMed]
41.
Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W, Jury J, Bolla M, Bercik P, Collins SM, Verdu E, Ongini E: Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 2011;141:1314-1322, 1322.e1-e5.
[PubMed]
https://doi.org/10.1053/j.gastro.2011.06.075
42.
Satoh H, Amagase K, Takeuchi K: Exacerbation of nonsteroidal anti-inflammatory drug-induced small intestinal lesions by antisecretory drugs in rats: the role of intestinal motility. J Pharmacol Exp Ther 2012;343:270-277.
[PubMed]
https://doi.org/10.1124/jpet.112.197475
43.
Satoh H, Amagase K, Takeuchi K: Mucosal protective agents prevent exacerbation of NSAID-induced small intestinal lesions caused by antisecretory drugs in rats. J Pharmacol Exp Ther 2014;348:227-235.
[PubMed]
https://doi.org/10.1124/jpet.113.208991
44.
Watanabe T, Tanigawa T, Nadatani Y, Nagami Y, Sugimori S, Okazaki H, Yamagami H, Watanabe K, Tominaga K, Fujiwara Y, Koike T, Arakawa T: Risk factors for severe nonsteroidal anti-inflammatory drug-induced small intestinal damage. Dig Liver Dis 2013;45:390-395.
[PubMed]
https://doi.org/10.1016/j.dld.2012.12.005
45.
Asako H, Kubes P, Wallace J, Gaginella T, Wolf RE, Granger DN: Indomethacin-induced leukocyte adhesion in mesenteric venules: role of lipoxygenase products. Am J Physiol 1992;262:G903-G908.
[PubMed]
46.
Nishio H, Hayashi Y, Terashima S, Takeuchi K: Protective effect of pranlukast, a cysteinyl-leukotriene receptor 1 antagonist, on indomethacin-induced small intestinal damage in rats. Inflammopharmacology 2007;15:266-272.
[PubMed]
https://doi.org/10.1007/s10787-007-1585-1
47.
Kubo Y, Kumano A, Kamei K, Amagase K, Abe N, Takeuchi K: Urocortin prevents indomethacin-induced small intestinal lesions in rats through activation of CRF2 receptors. Dig Dis Sci 2010;55:1570-1580.
[PubMed]
https://doi.org/10.1007/s10620-009-0930-1
48.
Wallace JL, Caliendo G, Santagada V, Cirino G, Fiorucci S: Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. Gastroenterology 2007;132:261-271.
[PubMed]
https://doi.org/10.1053/j.gastro.2006.11.042
49.
Wallace JL, Caliendo G, Santagada V, Cirino G: Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). Br J Pharmacol 2010;159:1236-1246.
[PubMed]
https://doi.org/10.1111/j.1476-5381.2009.00611.x
50.
Wallace JL: Physiological and pathophysiological roles of hydrogen sulfide in the gastrointestinal tract. Antioxid Redox Signal 2010;12:1125-1133.
[PubMed]
https://doi.org/10.1089/ars.2009.2900
51.
Blackler RW, Motta JP, Manko A, Workentine M, Bercik P, Surette MG, Wallace JL: Hydrogen sulphide protects against NSAID-enteropathy through modulation of bile and the microbiota. Br J Pharmacol 2015;172:992-1004.
[PubMed]
https://doi.org/10.1111/bph.12961
52.
Lanas A, Scarpignato C: Microbial flora in NSAID-induced intestinal damage: a role for antibiotics? Digestion 2006;73(suppl 1):136-150.
[PubMed]
https://doi.org/10.1159/000089789
53.
Takeuchi K, Yokota A, Tanaka A, Takahira Y,: Factors involved in upregulation of inducible nitric oxide synthase in rat small intestine following administration of nonsteroidal anti-inflammatory drugs. Dig Dis Sci 2006;51:1250-1259.
[PubMed]
https://doi.org/10.1007/s10620-006-8045-4
54.
van Klinken BJ, Einerhand AW, Büller HA, Dekker J: The oligomerization of a family of four genetically clustered human gastrointestinal mucins. Glycobiology 1988;8:67-75.
[PubMed]
https://doi.org/10.1093/glycob/8.1.67
55.
Amagase K, Kimura Y, Wada A, Yukishige T, Murakami T, Nakamura E, Takeuchi K: Prophylactic effect of monosodium glutamate on NSAID-induced enteropathy in rats. Curr Pharm Des 2014;20:2783-2790.
[PubMed]
https://doi.org/10.2174/13816128113199990579
56.
Hayashi S, Kurata N, Kitahirachi E, Nishimura Y, Amagase K, Yano T, Takeuchi K: Cinacalcet, a calcimimetic, prevents nonsteroidal antiinflammatory drug-induced small intestinal damage in rats. J Physiol Pharmacol 2013;64:453-463.
[PubMed]
57.
Hayashi S, Kurata N, Yamaguchi A, Amagase K, Takeuchi K: Lubiprostone prevents nonsteroidal anti-inflammatory drug-induced small intestinal damage by suppressing the expression of inflammatory mediators via EP4 receptors. J Pharmacol Exp Ther 2014;349:470-479.
[PubMed]
https://doi.org/10.1124/jpet.114.213991
58.
Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA: Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A 1990;87:1620-1624.
[PubMed]
https://doi.org/10.1073/pnas.87.4.1620
59.
Miller MJ, Thompson JH, Zhang XJ, Sadowska-Krowicka H, Kakkis JL, Munshi UK, Sandoval M, Rossi JL, Eloby-Childress S, Beckman JS, et al: Role of inducible nitric oxide synthase expression and peroxynitrite formation in guinea pig ileitis. Gastroenterology 1995;109:1475-1483.
[PubMed]
https://doi.org/10.1016/0016-5085(95)90633-9
60.
Bertrand V, Guimbaud R, Tulliez M, Mauprivez C, Sogni P, Couturier D, Giroud JP, Chaussade S, Chauvelot-Moachon L: Increase in tumor necrosis factor-alpha production linked to the toxicity of indomethacin for the rat small intestine. Br J Pharmacol 1998;124:1385-1394.
[PubMed]
https://doi.org/10.1038/sj.bjp.0701968
61.
Reuter BK, Wallace JL: Phosphodiesterase inhibitors prevent NSAID enteropathy independently of effects on TNF-alpha release. Am J Physiol 1999;277:G847-G854.
[PubMed]
62.
Tanaka A, Matsumoto M, Hayashi Y, Takeuchi K: Functional mechanism underlying cyclooxygenase-2 expression in rat small intestine following administration of indomethacin: relation to intestinal hypermotility. J Gastroenterol Hepatol 2005;20:38-45.
[PubMed]
https://doi.org/10.1111/j.1440-1746.2004.03520.x
63.
Watanabe T, Higuchi K, Kobata A, Nishio H, Tanigawa T, Shiba M, Tominaga K, Fujiwara Y, Oshitani N, Asahara T, Nomoto K, Takeuchi K, Arakawa T: Non-steroidal anti-inflammatory drug-induced small intestinal damage is toll-like receptor 4 dependent. Gut 2008;57:181-187.
[PubMed]
https://doi.org/10.1136/gut.2007.125963
64.
Kato S, Ito Y, Nishio H, Aoi Y, Amagase K, Takeuchi K: Increased susceptibility of small intestine to NSAID-provoked ulceration in rats with adjuvant-induced arthritis: involvement of enhanced expression of TLR4. Life Sci 2007;81:1309-1316.
[PubMed]
https://doi.org/10.1016/j.lfs.2007.08.036
65.
Edogawa S, Sakai A, Inoue T, Harada S, Takeuchi T, Umegaki E, Hayashi H, Higuchi K: Down-regulation of collagen I biosynthesis in intestinal epithelial cells exposed to indomethacin: a comparative proteome analysis. J Proteomics 2014;103:35-46.
[PubMed]
https://doi.org/10.1016/j.jprot.2014.03.022
66.
Narabayashi K, Ito Y, Eid N, Maemura K, Inoue T, Takeuchi T, Otsuki Y, Higuchi K: Indomethacin suppresses LAMP-2 expression and induces lipophagy and lipoapoptosis in rat enterocytes via the ER stress pathway. J Gastroenterol 2014, Epub ahead of print.
[PubMed]
https://doi.org/10.1007/s00535-014-0995-2
67.
Schey R, Rao SS: Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome. Dig Dis Sci 2011;56:1619-1625.
[PubMed]
https://doi.org/10.1007/s10620-011-1702-2
68.
Belley A, Chadee K: Prostaglandin E(2) stimulates rat and human colonic mucin exocytosis via the EP(4) receptor. Gastroenterology 1999;117:1352-1362.
[PubMed]
https://doi.org/10.1016/S0016-5085(99)70285-4
69.
Takahashi S, Takeuchi K, Okabe S: EP4 receptor mediation of prostaglandin E2-stimulated mucus secretion by rabbit gastric epithelial cells. Biochem Pharmacol 1999;58:1997-2002.
[PubMed]
https://doi.org/10.1016/S0006-2952(99)00286-5
70.
Satoh H, Guth PH, Grossman MI: Role of food in gastrointestinal ulceration produced by indomethacin in the rat. Gastroenterology 1982;83:210-215.
[PubMed]
71.
Satoh H, Amagase K, Takeuchi K: The role of food for the formation and prevention of gastrointestinal lesions induced by aspirin in cats. Dig Dis Sci 2013;58:2840-2849.
[PubMed]
https://doi.org/10.1007/s10620-013-2725-7
72.
Robert A, Hanchar AJ, Lancaster C, Nezamis JE: Anti-ulcer effect of aspirin. Gastroenterology 1973;72:A-97.
73.
Robert A: Gastric cytoprotection by sodium salicylate. Prostaglandins 1981;21:139-146.
[PubMed]
https://doi.org/10.1016/0090-6980(81)90130-1
© 2015 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2015
You do not currently have access to this content.